Kazia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 12, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Cap	156	10	8	26	58	130
Market Cap Growth	1622.15%	33.16%	-71.18%	-54.61%	-55.23%	305.89%
Enterprise Value	110.05	-13.55	6.94	24.16	54.47	109.48
Last Close Price	13.68	6.27	11.45	58.00	210.00	493.00
PS Ratio	125.24	369.56	4.95	-	-	11.43
PB Ratio	5.08	0.29	-1.14	3.29	4.62	4.59
P/TBV Ratio	0.08	0.20	-	-	-	9.76
EV/Sales Ratio	88.71	-493.34	4.51	-	-	9.62
EV/EBITDA Ratio	-	1.56	-	-	-	-
EV/EBIT Ratio	-	1.46	-	-	-	-
EV/FCF Ratio	-	1.54	-	-	-	-
Debt / Equity Ratio	0.05	0.06	0	0	0	0
Net Debt / Equity Ratio	-0.66	-0.69	0.10	-0.29	-0.30	-0.73
Net Debt / EBITDA Ratio	1.11	2.79	0.04	0.16	0.23	5.39
Net Debt / FCF Ratio	1.65	2.76	0.11	0.23	0.24	3.03
Asset Turnover	-	0.00	0.09	0	0	0.38
Quick Ratio	7.44	8.22	0.22	1.21	1.11	3.32
Current Ratio	8.61	9.60	0.24	1.42	1.40	3.53
Return on Equity (ROE)	-64.40%	-94.36%	-2660.19%	-132.16%	-84.19%	-33.12%
Return on Assets (ROA)	-51.99%	-31.13%	-114.94%	-73.06%	-50.62%	-15.21%
Return on Invested Capital (ROIC)	-164.16%	-218.24%	-1503.51%	-236.08%	-223.32%	-77.22%
Return on Capital Employed (ROCE)	-61.04%	-54.18%	-354.04%	-95.24%	-61.10%	-19.24%
Buyback Yield / Dilution	-213.01%	-107.81%	-43.08%	-39.12%	-12.57%	-61.08%
Total Shareholder Return	-213.01%	-107.81%	-43.08%	-39.12%	-12.57%	-61.08%

SEC Filings: 10-K · 10-Q